Monoclonal antibody for the diagnosis, treatment and/or prevention of brain tumors and brain lesions
AssigneesAlthia Health, S.L., Consejo Superior De Investigaciones Cientificas (Csic)
InventorsAugusto SILVA GONZÁLEZ, José Alberto GARCÍA SANZ
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of the monoclonal antibody NILO1 for the diagnosis, treatment and/or prevention of brain tumors and lesions. Particularly, the invention relates to methods for the diagnosis of brain tumors and brain lesions in which cells marked with said antibody, or with immunologically active fragments thereof, are detected. The invention also relates to the use of said monoclonal antibody, or immunologically active fragments thereof, as a medicament for the treatment and/or prevention of brain tumors and brain lesions. In a preferred embodiment of the invention, the monoclonal antibody NILO1, or its immunologically active fragments, are humanized.
Claims15
Use of a monoclonal antibody, called NILO1, produced by the hybridoma deposited under the DSM access number No. ACC2887, or an immunologically active fragment thereof, for the manufacture of a reactive for the diagnosis of brain tumors and lesions.
A monoclonal antibody, called NILO1, produced by the hybridoma deposited under the DSM access number No. ACC2887, or an immunologically active fragment thereof, for use as a medicament.
The monoclonal antibody, called NILO1, produced by the hybridoma deposited under the DSM access number No. ACC2887, or an immunologically active fragment thereof, for use in the treatment and/or prevention of brain tumors or lesions, preferably wherein the brain lesion is produced by a neurodegenerative process, demyelination, mechanical injury or stroke, and the brain tumor is glioblastoma.
A method for the in vitro diagnosis of brain tumors, more preferably glioblastoma, which comprises:
- a. Putting in contact an isolated biological sample with the monoclonal antibody called NILO1, produced by the hybridoma deposited under the DSM access number No. ACC2887, or an immunologically active fragment thereof,
- b. detecting, preferably by flow cytometry, immunohistochemistry, ELISA, and/or Western Blot, the presence of cells marked with the antibody or an immunologically active fragment thereof, and
- c. associate the presence of said cells to a brain tumor.
A method for obtaining data for the diagnosis of a brain tumor or lesion, preferably brain lesions produced by a neurodegenerative process, demyelination, mechanical injury or stroke, which comprises:
- a. detecting the presence of cells marked with the monoclonal antibody, called NILO1, produced by the hybridoma deposited under the DSM access number No. ACC2887, or an immunologically active fragment thereof, in the brain of a subject previously injected with said antibody or an immunologically active fragment thereof,
- wherein the step (a) is preferably performed by magnetic resonance imaging, flow cytometry, immunohistochemistry, ELISA, and/or Western Blot, more preferably by magnetic resonance imaging.
A monoclonal antibody, called NILO1, produced by the hybridoma deposited under the DSM access number No. ACC2887, or an immunologically active fragment thereof, coupled to a support, an active principle and/or a particle, wherein preferably the active principle is a drug and more preferably the particle is a nanoparticle, more preferably magnetic nanoparticle, more preferably magnetic glyconanoparticle, even more preferably wherein said nanoparticle further comprises a G protein immobilized in its surface.
Dependencies are inferred from the claim text.